MedPath

Olanzapine

Generic Name
Olanzapine
Brand Names
Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark, Olanzapine Viatris (previously Olanzapine Mylan)
Drug Type
Small Molecule
Chemical Formula
C17H20N4S
CAS Number
132539-06-1
Unique Ingredient Identifier
N7U69T4SZR

Overview

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Background

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes. Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults. As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old. Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania. Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking. Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania. Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions

  • Acute Agitation
  • Bipolar 1 Disorder
  • Bipolar Disorder With Manic or Mixed Episodes
  • Delirium
  • Delusional Parasitosis
  • Depressive Episodes
  • Gilles de la Tourette's Syndrome
  • Major depressive disorder, recurrent episode
  • Mixed manic depressive episode
  • Post Traumatic Stress Disorder (PTSD)
  • Psychosis
  • Schizophrenia
  • Acute Manic episode

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2015/12/18
Phase 3
Completed
2015/11/09
N/A
Completed
2015/11/01
Phase 4
Completed
University of Ghana Medical School
2015/10/21
N/A
Completed
Canadian Network for Observational Drug Effect Studies, CNODES
2015/09/29
Phase 4
UNKNOWN
2015/09/01
Phase 4
Completed
Dost Ongur
2015/06/30
Phase 3
Completed
First Affiliated Hospital of Harbin Medical University
2015/06/04
Phase 2
Terminated
2015/05/19
Phase 1
Completed
Michael Rickels
2015/05/06
Phase 4
Completed
Kunming Medical University

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
H2-Pharma LLC
61269-635
ORAL
20 mg in 1 1
10/9/2023
Zydus Lifesciences Limited
70771-1416
ORAL
2.5 mg in 1 1
9/27/2023
Torrent Pharmaceuticals Limited
13668-088
ORAL
10 mg in 1 1
12/8/2022
Aurobindo Pharma Limited
65862-658
ORAL
15 mg in 1 1
5/3/2020
PD-Rx Pharmaceuticals, Inc.
72789-265
ORAL
5 mg in 1 1
3/25/2024
Major Pharmaceuticals
0904-6283
ORAL
2.5 mg in 1 1
12/11/2022
Cardinal Health 107, LLC
55154-6889
ORAL
10 mg in 1 1
12/20/2022
Bryant Ranch Prepack
63629-8719
ORAL
20 mg in 1 1
10/14/2021
Qilu Pharmaceutical Co., Ltd.
67184-0561
ORAL
2.5 mg in 1 1
5/1/2018
Eli Lilly and Company
0002-4115
ORAL
5 mg in 1 1
11/11/2022

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath